HCW Biologics reports financial results for 2024 and progress in clinical trials.

From GlobeNewswire: 2025-03-28 15:30:00

HCW Biologics Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2024. CEO Dr. Wong highlighted the start of clinical trials for HCW9302 in alopecia areata and the development of 50 compounds for various diseases using the TRBC platform.
The company entered a licensing agreement with WY Biotech in 2024 and raised $16.3 million through various financing transactions. Compliance with Nasdaq listing rules is being addressed, with a Special Meeting of Stockholders scheduled for March 31, 2025.
Clinical development results show FDA clearance for a Phase 1 trial of HCW9302 for alopecia areata. Financially, revenues decreased in 2024 compared to 2023, while R&D expenses and legal fees also saw changes.
HCW Biologics faces significant financial challenges, with doubts about continued operation without additional funding. The company is working on financing plans and future capital-raising activities, with Maxim Group LLC acting as the Placement Agent.
HCW Biologics is focused on developing immunotherapies to combat age-related diseases. The company’s drug discovery platforms, TOBI™ and TRBC, aim to create multi-functional fusion molecules for various conditions. Forward-looking statements indicate potential challenges and opportunities for the company.



Read more at GlobeNewswire:: HCW Biologics Reports Fourth Quarter and Fiscal Year